Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.56 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561292 | 1.00 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL6638467 | 0.94 | ITGB1 (0.63) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL6561608 | 0.91 | ITGB1 (0.69) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL27543603 | 0.91 | ITGB1 (0.69) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL15140552 | 0.90 | ITGB1 (0.48) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL15140555 | 0.90 | ITGB1 (0.48) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL6512177 | 0.88 | ITGB1 (0.53) | ITGB1ITGA4ITGB3ITGAVITGA2B | |
| SCHEMBL7480195 | 0.85 | KLK5 (0.43) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL7104140 | 0.85 | KLK5 (0.46) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL7480191 | 0.85 | KLK5 (0.43) | ITGB1ITGA4ITGA2ITGB7ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491178-B2 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | HOFFMANN-LA ROCHE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| EP-2806896-B1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| EP-2806897-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1 | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9650363-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 | HOFFMANN-LA ROCHE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-9447035-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
| EP-2806898-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| EP-2806896-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110578-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110681-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110679-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013110680-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110681-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | ARROWHEAD RESEARCH CORPORATION (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | ITGB1 1/4885ITGA4 2/4885ITGA2 9/4885 |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGA1 | ITGB1 1/4885ITGA4 2/4885ITGA2 8/4885 |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | ITGAV, ITGA1, ITGA4 | ITGB1 6/4885ITGA4 3/4885ITGA2 4/4885 |
| US-11491178-B2 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | ITGB1, ITGA4, ITGB4 | ITGB1 1/4885ITGA4 2/4885ITGA2 9/4885 |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | LPAR4, ASGR1, VCAM1 | ITGB1 20/4885ITGA4 4/4885ITGA2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.